BioNxt Solutions Inc.
BNXT
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.90K | 22.70K | 153.80K | 276.10K | 288.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.90K | 22.70K | 153.80K | 276.10K | 288.40K |
| Cost of Revenue | -- | -- | -- | -- | 106.30K |
| Gross Profit | 30.90K | 22.70K | 153.80K | 276.10K | 182.10K |
| SG&A Expenses | 2.29M | 2.06M | 2.95M | 2.95M | 3.09M |
| Depreciation & Amortization | 82.40K | 101.60K | 125.80K | 145.20K | 150.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.97M | 3.80M | 4.89M | 4.99M | 4.96M |
| Operating Income | -3.94M | -3.77M | -4.74M | -4.71M | -4.67M |
| Income Before Tax | -4.77M | -4.74M | -5.78M | -5.72M | -9.69M |
| Income Tax Expenses | -- | -- | -- | -- | -363.90K |
| Earnings from Continuing Operations | -4.77 | -4.74 | -5.78 | -5.72 | -9.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.77M | -4.74M | -5.78M | -5.72M | -9.33M |
| EBIT | -3.94M | -3.77M | -4.74M | -4.71M | -4.67M |
| EBITDA | -3.86M | -3.68M | -4.62M | -4.57M | -4.56M |
| EPS Basic | -0.04 | -0.05 | -0.06 | -0.06 | -0.10 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.04 | -0.05 | -0.06 | -0.06 | -0.10 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 437.31M | 423.11M | 411.75M | 396.37M | 382.11M |
| Average Diluted Shares Outstanding | 437.31M | 423.11M | 411.75M | 396.37M | 382.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
